The litigation centers on a March 2026 report by Culper Research, which accused the Ramsey, New Jersey-based firm of inflating financial results. Analysts alleged that ADMA engaged in channel stuffing, offering rebates and extended payment terms to distributors to artificially bolster sales of its flagship immune globulin product, ASCENIV. The report claimed that without these practices, the company would have faced a 3% revenue decline in 2025 rather than the reported 20% growth.
In section Releases
Investors Face August 10 Deadline in ADMA Biologics Class Action
Investors who held ADMA Biologics stock between August 2024 and March 2026 have until August 10, 2026, to seek lead plaintiff status in a pending securities fraud lawsuit. The Philadelphia-based law firm Berger Montague launched the action following allegations of deceptive revenue reporting practices at the biopharmaceutical company.
Market reaction to the allegations was immediate. ADMA shares dropped 16% on March 24, 2026, falling from $13.59 to $11.33. The sell-off continued the following day, with the stock price sliding another 15% to close at $9.63. Investors seeking to participate in the case or discuss their legal rights are directed to contact Berger Montague attorneys Andrew Abramowitz or Caitlin Adorni.
Comments (0)
No comments yet. Be the first!